Evista to PREVENT breast cancer
May 2006
More women will be taking Evista to PREVENT breast cancer.
Preliminary results of the STAR study show that Evista (raloxifene) really does work as well as tamoxifen to reduce the risk of invasive breast cancer...and it's better tolerated.
Both drugs cut the number of expected breast cancer cases from 40 to 20 per 1000 postmenopausal women.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote